AvenCell Therapeutics, Inc

General information
AvenCell Therapeutics, Inc
500 Forge Road
Suite 302
02472 Watertown, Massachusetts
USA

Contact person: Andrew Schiermeier, Chief Executive Officer
Company main phone: +1 (617) 9417468
Website:  https://avencell.com
Year founded:2021
Source of foundation:Independent foundation
Corporate description / mission:
AvenCell Therapeutics is a clinical-stage biotechnology company developing next-generation cell immunotherapies for the treatment of difficult-to-treat cancers. The company focuses on engineering switchable and allogeneic CAR-T cell therapies designed to improve the safety, persistence, and flexibility of adoptive cell therapies for hematologic malignancies and solid tumors. The company's technology platform combines proprietary universal switchable CAR-T technology with CRISPR-based allogeneic cell engineering to develop both autologous and off-the-shelf cell therapy candidates.
State of ownership: Private / independent
Headquarters: HQ: Yes
Categorization
Sector:
  • Biotechnology - Therapeutics and Diagnostics
Subsector:
  • Cell therapy
  • Immunotherapy
Primary therapeutic areas:
  • Neoplasms / cancer / oncology
  • Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Business model:
  • R&D
Customer segments:
  • Other
  • Hospitals
  • Large biotech & big pharma
  • Small biotech
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical:4
Phase II:1
Description of products:
AVC-201
AVC-202
AVC-203 etc.
Technology used:
UniCAR, RevCAR and TCE
Collaborations & Clients
Partnering strategy / collaborations:
Intellia Therapeutics
Blackstone Lifesciences
© 2026 Biotechgate by Venture Valuation
X